Floatz Rating
C36/100
Confidence
Indicative
Sponsor
Hrain Biotechnology Co., Ltd.
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06045091CT.gov To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Bcma Targeted Car-Nk Cells (this asset) | Hrain Biotechnology Co., Ltd. | Early P1 | C · 36 |
| Cyclophosphamide | Institute of Hematology & Blood Diseases Hospital, China | P2 | BB |
| Fludarabine | Masonic Cancer Center, University of Minnesota | P2 | BB |
| Melphalan | National Cancer Institute (NCI) | P2 | B |
| Lenalidomide | National Cancer Institute (NCI) | P3 | B |
| Dexasone | National Cancer Institute (NCI) | P3 | B |
| Daratumumab | National Cancer Institute (NCI) | P3 | B |
| Tacrolimus | Masonic Cancer Center, University of Minnesota | P2 | B |
| Teclistamab | National Cancer Institute (NCI) | P3 | B |
+42 more in the Plasma Cell Leukemia cohort
Other indications for Human Bcma Targeted Car-Nk Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | Early P1 | C · 33 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Human Bcma Targeted Car-Nk Cells in Plasma Cell Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-bcma-targeted-car-nk-cells-plasma-cell-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →